CDT Stock Research Snapshot: Pipeline, Catalysts, and Cash Runway

CDT Equity Inc | Needs refresh | Last updated: 2026-06-01T17:55:29Z

TickerCDT

Market Cap4.4M

Cash RunwayRunway < 6 months

Next Catalyst2026-10-20

Public Research Snapshot

CDT Equity Inc is a publicly tracked healthcare company. This research snapshot summarizes public information on pipeline assets, clinical trials, upcoming catalysts, SEC filings, and cash runway estimates for Litifilimab in Subacute Cutaneous Lupus Erythematosus | Chronic Cutaneous Lupus Erythematosus (Phase 2 | Phase 3).

Pipeline

Asset	Indication	Modality	Stage	Public Note
Litifilimab	Subacute Cutaneous Lupus Erythematosus \| Chronic Cutaneous Lupus Erythematosus	n/a	Phase 2 \| Phase 3	Public pipeline row

Catalyst Preview

Company	Ticker	Catalyst	Timing	Asset	Confidence
		Clinical Trial Completion	2026-10-20	Litifilimab	Low

Cash Runway Preview

Estimated cash runway: Runway < 6 months.

This is an automated estimate and may differ from company guidance.

Recent SEC Filings

No public filing rows are loaded yet.

Clinical Trial Activity

NCT ID	Phase	Status	Enrollment	Primary Completion
NCT05531565	Phase 2 \| Phase 3	RECRUITING	450	2026-10-20

Scientific Context

literature_publication | Reperfusion treatment strategies in acute pulmonary embolism: Study protocol for a multicenter prospective observational study in the Nordic countries (PE-NORDIC).
literature_publication | Trends in catheter-directed therapy and in-hospital outcomes among patients with acute pulmonary embolism: insights from a multicentre national quality assurance database registry.
literature_publication | AI and machine learning in nutrition: the promise, the challenge, and recommendations.
literature_publication | Artificial intelligence in cardiology: a narrative review with focus on patient outcomes.
literature_publication | Large-Bore Mechanical Thrombectomy Versus Catheter-Directed Thrombolysis in the Management of Intermediate-Risk Pulmonary Embolism: Primary Results of the PEERLESS Randomized Controlled Trial.

Want the full CDT research brief?

Subscribe for source-linked catalyst analysis, cash runway monitoring, and clinical trial change alerts.

Get the weekly biotech catalyst watchlist

This page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell securities. Data may be incomplete or delayed. Cash runway and catalyst timing estimates are derived from public sources and may differ from company guidance.